C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer

C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer

(2018) Mei-Chun Lin et al.   ONCOGENE

Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer

(2018) Maolin Chu et al.   Scientific Reports

Epidermal growth factor receptor inhibition downregulatesHelicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis

(2017) Johanna C Sierra et al.   GUT

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

(2017) Conor A. Bradley et al.   Nature Reviews Clinical Oncology

EphA2 is a functional receptor for the growth factor progranulin

(2016) Thomas Neill et al.   JOURNAL OF CELL BIOLOGY

Mechanisms of ephrin–Eph signalling in development, physiology and disease

(2016) Artur Kania et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Probing the O-Glycoproteome of Gastric Cancer Cell Lines for Biomarker Discovery

(2015) Diana Campos et al.   MOLECULAR & CELLULAR PROTEOMICS

Movers and shakers: cell cytoskeleton in cancer metastasis

(2014) C M Fife et al.   BRITISH JOURNAL OF PHARMACOLOGY

Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis

(2014) Zhi Peng et al.   PLoS One

C1galt1-deficient mice exhibit thrombocytopenia due to abnormal terminal differentiation of megakaryocytes

(2013) T. Kudo et al.   BLOOD

Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells

(2013) Yasumitsu Uchida et al.   CANCER BIOLOGY & THERAPY

C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization

(2013) Y.-M. Wu et al.   CANCER RESEARCH

Mucin-typeO-Glycosylation during Development

(2013) Duy T. Tran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic targeting of EPH receptors and their ligands

(2013) Andrew W. Boyd et al.   NATURE REVIEWS DRUG DISCOVERY

ADAM12-cleaved ephrin-A1 contributes to lung metastasis

(2013) K Ieguchi et al.   ONCOGENE

Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness

(2013) David J. Gill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Eph receptors and ephrins as targets for cancer therapy

(2012) Hong-Qing Xi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Mucin Glycosylating Enzyme GALNT2 Regulates the Malignant Character of Hepatocellular Carcinoma by Modifying the EGF Receptor

(2011) Y.-M. Wu et al.   CANCER RESEARCH

Ephs and ephrins in cancer: Ephrin-A1 signalling

(2011) Amanda Beauchamp et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

7th Edition of the AJCC Cancer Staging Manual: Stomach

(2010) Kay Washington   ANNALS OF SURGICAL ONCOLOGY

Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells

(2010) Spencer Alford et al.   Cancer Cell International

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients

(2008) Wei-Jie Yuan et al.   DIGESTIVE DISEASES AND SCIENCES

Recent insights into the biological roles of mucin-type O-glycosylation

(2008) E Tian et al.   GLYCOCONJUGATE JOURNAL

The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting

(2008) J. Wykosky et al.   MOLECULAR CANCER RESEARCH